Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · IEX Real-Time Price · USD
68.68
-1.18 (-1.69%)
May 31, 2024, 4:00 PM EDT - Market closed
Dr. Reddy's Laboratories Employees
Dr. Reddy's Laboratories had 25,863 employees on March 31, 2023. The number of employees increased by 1,068 or 4.31% compared to the previous year.
Employees
25,863
Change (1Y)
1,068
Growth (1Y)
4.31%
Revenue / Employee
$115,657
Profits / Employee
$21,199
Market Cap
11.43B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 31, 2023 | 25,863 | 1,068 | 4.31% |
Mar 31, 2022 | 24,795 | 2,056 | 9.04% |
Mar 31, 2021 | 22,739 | 1,089 | 5.03% |
Mar 31, 2020 | 21,650 | -316 | -1.44% |
Mar 31, 2019 | 21,966 | -1,558 | -6.62% |
Mar 31, 2018 | 23,524 | 853 | 3.76% |
Mar 31, 2017 | 22,671 | 496 | 2.24% |
Mar 31, 2016 | 22,175 | 1,802 | 8.85% |
Mar 31, 2015 | 20,373 | 1,952 | 10.60% |
Mar 31, 2014 | 18,421 | 1,804 | 10.86% |
Mar 31, 2013 | 16,617 | 1,417 | 9.32% |
Mar 31, 2012 | 15,200 | 277 | 1.86% |
Mar 31, 2011 | 14,923 | 1,468 | 10.91% |
Mar 31, 2010 | 13,455 | 2,227 | 19.83% |
Mar 31, 2009 | 11,228 | 1,653 | 17.26% |
Mar 31, 2008 | 9,575 | 555 | 6.15% |
Mar 31, 2007 | 9,020 | 1,495 | 19.87% |
Mar 31, 2006 | 7,525 | 1,390 | 22.66% |
Mar 31, 2005 | 6,135 | -20 | -0.32% |
Mar 31, 2004 | 6,155 | 303 | 5.18% |
Mar 31, 2003 | 5,852 | 409 | 7.51% |
Mar 31, 2002 | 5,443 | 314 | 6.12% |
Mar 31, 2001 | 5,129 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Universal Health Services | 96,700 |
Charles River Laboratories International | 21,800 |
Smith & Nephew | 19,081 |
Teleflex | 14,500 |
Medpace Holdings | 5,900 |
Bio-Techne | 3,050 |
Sarepta Therapeutics | 1,314 |
United Therapeutics | 1,168 |
RDY News
- 5 days ago - Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America - Business Wire
- 12 days ago - Alvotech and Dr. Reddy's Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK - Business Wire
- 26 days ago - Dr. Reddy's Q4 & Full Year FY24 Financial Results - Business Wire
- 4 weeks ago - Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S. - Business Wire
- 2 months ago - Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK - Business Wire
- 4 months ago - Dr. Reddy's Q3 & 9M FY24 Financial Results - Business Wire
- 5 months ago - Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women's Health and Dietary Supplements Portfolio of Brands - Business Wire
- 6 months ago - Dr. Reddy's becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index - Business Wire